ARCHIVES

Trading In Stock Of U.S. Bioscience Halted, Newsletter Report Cited

This article is from The Cancer Letter archive.

Vol. 18 No. 39 | October 9, 1992

Download PDF Visit The Full Archive

Related Articles

Blinatumomab Demonstrates High Response Rate in ALL

June 29, 2012

Modeling Will Be Used For Other Populations

November 26, 2010

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008

NCI “Month” Appropriate For May, With Several Major Decisions Pending got Start Next 50 Years

May 1, 1987

Novartis Begins Study Of Femara And Zometa In Postmenopausal Early Breast Cancer

December 27, 2002

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

December 30, 2011